-
Mashup Score: 7Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid Leukemia - 1 month(s) ago
As specialists in adult leukemia, we have grown accustomed to the jibes from oncologists focused on other diseases: “So are you still giving 3 + 7?” Yes, it is true; for patients with acute myeloid leukemia (AML) who are not enrolled onto a clinical trial, we indeed regularly administer the same cytotoxic 7-day anthracycline/cytarabine combination chemotherapy regimens (3 + 7) that became standard care for AML in the 1970s, back when each of us was playing Little League baseball. 1 For a while, we could
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22
Roivant’s Hemavant has
Source: www.fiercebiotech.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Spotlight on lower-risk MDS - 2 month(s) ago
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 29Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country - 2 month(s) ago
PURPOSE Myelodysplastic syndromes (MDS) include a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis. They manifest as dysplasia in bone marrow hemopoietic elements associated with peripheral cytopenias with variable risk of AML transformation. PATIENTS AND METHODS We analyzed retrospectively registry data collected prospectively from patients with primary MDS and patients with MDS/myeloproliferative neoplasm (MPN) in the Jordan University Hospital between January 2007 and September 2021. The registry captured epidemiologic information such as date of diagnosis, age, gender, date of AML transformation, cytogenetics, MDS subtype, risk group according to Revised International Prognostic Scoring System, and survival. The registry also captured baseline ferritin, B12, and lactate dehydrogenase levels. RESULTS A total of 112 patients with MDS and MDS/MPN were included in the registry. Median age at diagnosis was 59 years. The male-to-female ratio
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10DOM MGR - Katten Memorial Lectureship 2/20/2024 - 2 month(s) ago
**Medical Grand Rounds** We are honored to host Amer Zeidan, MBBS, MHS; Interim Chief, Hematologic Malignancies; Associate Professor of Medicine from Yale University for…
Source: planitpurple.northwestern.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 - 2 month(s) ago
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;…
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 - 3 month(s) ago
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;…
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 58Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”? - 3 month(s) ago
Key Points. Historical monotherapy trials with azacitidine or decitabine confirm generally low CR rates (14% of patients).The DNMTI used may influence responses
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
With development of magrolimab & sabatolimab now halted in #MDSsm, re-sharing analysis with @andrewbrunner of when early results with HMA combination therapy are truly promising. Both drugs would not have passed the test, yet large investments were made. https://t.co/cVqTiTMnM3 https://t.co/Gdj46EuRs0
-
-
Mashup Score: 9
Myelodysplastic syndromes (MDS) encompass a heterogeneous set of acquired bone marrow neoplastic disorders characterized by ineffective hematopoiesis within one or more bone marrow lineages. Nearly h…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Spotlight on lower-risk MDS - 3 month(s) ago
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
@MikkaelSekeres @farrellybros Thanks @MikkaelSekeres and @ramsedhom! I appreciate the "wicked awesome" shout outs! (That's RI lingo for really nice 😆) @MikkaelSekeres I was inspired by your MDS editorial that worked in the title of a Green Day song: https://t.co/yibP5yO8p1 #mdssm